These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 33951360)

  • 1. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
    Dorman SE; Nahid P; Kurbatova EV; Phillips PPJ; Bryant K; Dooley KE; Engle M; Goldberg SV; Phan HTT; Hakim J; Johnson JL; Lourens M; Martinson NA; Muzanyi G; Narunsky K; Nerette S; Nguyen NV; Pham TH; Pierre S; Purfield AE; Samaneka W; Savic RM; Sanne I; Scott NA; Shenje J; Sizemore E; Vernon A; Waja Z; Weiner M; Swindells S; Chaisson RE; ;
    N Engl J Med; 2021 May; 384(18):1705-1718. PubMed ID: 33951360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
    N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
    Pettit AC; Phillips PPJ; Kurbatova E; Vernon A; Nahid P; Dawson R; Dooley KE; Sanne I; Waja Z; Mohapi L; Podany AT; Samaneka W; Savic RM; Johnson JL; Muzanyi G; Lalloo UG; Bryant K; Sizemore E; Scott N; Dorman SE; Chaisson RE; Swindells S;
    Clin Infect Dis; 2023 Feb; 76(3):e580-e589. PubMed ID: 36041016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH; Crook AM; McHugh TD; Mendel CM; Meredith SK; Murray SR; Pappas F; Phillips PP; Nunn AJ;
    N Engl J Med; 2014 Oct; 371(17):1577-87. PubMed ID: 25196020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
    Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
    Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
    Nunn AJ; Phillips PPJ; Meredith SK; Chiang CY; Conradie F; Dalai D; van Deun A; Dat PT; Lan N; Master I; Mebrahtu T; Meressa D; Moodliar R; Ngubane N; Sanders K; Squire SB; Torrea G; Tsogt B; Rusen ID;
    N Engl J Med; 2019 Mar; 380(13):1201-1213. PubMed ID: 30865791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A four-month gatifloxacin-containing regimen for treating tuberculosis.
    Merle CS; Fielding K; Sow OB; Gninafon M; Lo MB; Mthiyane T; Odhiambo J; Amukoye E; Bah B; Kassa F; N'Diaye A; Rustomjee R; de Jong BC; Horton J; Perronne C; Sismanidis C; Lapujade O; Olliaro PL; Lienhardt C;
    N Engl J Med; 2014 Oct; 371(17):1588-98. PubMed ID: 25337748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Solodovnikova V; Liverko I; Moodliar R; Dodd M; Ngubane N; Rassool M; McHugh TD; Spigelman M; Moore DAJ; Ritmeijer K; du Cros P; Fielding K;
    N Engl J Med; 2022 Dec; 387(25):2331-2343. PubMed ID: 36546625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
    Paton NI; Cousins C; Suresh C; Burhan E; Chew KL; Dalay VB; Lu Q; Kusmiati T; Balanag VM; Lee SL; Ruslami R; Pokharkar Y; Djaharuddin I; Sugiri JJR; Veto RS; Sekaggya-Wiltshire C; Avihingsanon A; Sarin R; Papineni P; Nunn AJ; Crook AM;
    N Engl J Med; 2023 Mar; 388(10):873-887. PubMed ID: 36808186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
    Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
    Carr W; Kurbatova E; Starks A; Goswami N; Allen L; Winston C
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(8):285-289. PubMed ID: 35202353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.